[1]徐彤,甘霞,袁今奇.消胀方联合拉米夫定对代偿期乙型肝炎肝硬化患者肝功能及肝纤维化程度的影响[J].甘肃中医药大学学报,2018,35(04):53-56.[doi:10.16841/j.issn1003-8450.2018.04.12]
 XU Tong,GAN Xia,YUAN Jinqi.Effect of Xiaozhang Fang combined with lamivudine on liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis[J].Journal of Gansu University of Chinese Medicine,2018,35(04):53-56.[doi:10.16841/j.issn1003-8450.2018.04.12]
点击复制

消胀方联合拉米夫定对代偿期乙型肝炎肝硬化患者肝功能及肝纤维化程度的影响()
分享到:

《甘肃中医药大学学报》[ISSN:1003-8450/CN:62-1062/R]

卷:
35卷
期数:
2018年04期
页码:
53-56
栏目:
临床研究与报道
出版日期:
2018-08-25

文章信息/Info

Title:
Effect of Xiaozhang Fang combined with lamivudine on liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis
作者:
徐彤 甘霞 袁今奇
石河子大学医学院第一附属医院中医科, 新疆 石河子 832008
Author(s):
XU Tong GAN Xia YUAN Jinqi
Department of Chinese Medicine, the First Affiliated Hospital of Clinical College of Medicine, Shihezi University, Shihezi, Xinjiang, 832008, China
关键词:
代偿期乙型肝炎肝硬化消胀方拉米夫定肝功能肝纤维化肝脏硬度值临床观察
Keywords:
hepatitis B virus-related compensated cirrhosisXiaozhang Fanglamivudineliver functionliver fibrosisliver hardness numberclinical observation
分类号:
R259.126+.2
DOI:
10.16841/j.issn1003-8450.2018.04.12
摘要:
目的 研究消胀方联合拉米夫定对代偿期乙型肝炎肝硬化患者肝功能、血清肝纤维化指标及肝脏硬度值的影响。方法 将70例代偿期乙型肝炎肝硬化患者随机分为治疗组和对照组,各35例。对照组予扶正化瘀胶囊联合拉米夫定治疗,治疗组予消胀方联合拉米夫定治疗,2组均治疗12月。治疗前后比较2组的肝功能、血清肝纤维化指标及肝脏硬度值,并观察2组不良反应发生情况。结果 治疗后2组血清肝纤维化指标及肝脏硬度值均明显降低,肝功能指标明显改善,与同组治疗前比较差异均有统计学意义(P<0.05),且治疗组改善程度明显优于对照组(P<0.05);2组在治疗过程中均未发生明显不良反应。结论 消胀方联合拉米夫定能明显改善代偿期乙型肝炎肝硬化患者的肝功能及肝脏纤维化程度,且无明显不良反应,值得在临床上推广运用。
Abstract:
Objective To observe the effect of Xiaozhang Fang combined with lamivudine on liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis. Methods 70 patients with hepatitis B virus-related compensated cirrhosis were divided into two groups (35 cases in each group). The control group was given Fuzheng Huayu Capsules combined with lamivudine,but the treatment group was given Xiaozhang Fang combined with lamivudine. Both were treated for 12 months. Then,liver function and liver fibrosis index in serum as well as liver hardness number were compared between two groups before and after treatment,and the adverse effects were observed. Results After treatment,liver fibrosis index in serum and liver hardness number of the two groups both dropped noticeably,and liver function index improved significantly. The differences before and after treatment were significant (P<0.05),and the reduction was more in treatment group than in control group (P<0.05).There were no adverse effects in two groups. Conclusion Xiaozhang Fang combined with lamivudine can improve the liver function and liver fibrosis degree in patients with hepatitis B virus-related compensated cirrhosis without obvious adverse effects,which is worthy of clinical promotion and application.

参考文献/References:

[1] 任丽楠,祁兴顺,陈江,等.不同病因肝硬化患者血清肝纤维化指标结果分析[J]. 胃肠病学和肝病学杂志,2017,26(1):346-347.
[2] Mao H,Kang T.Lactic acidosis during entecavir antiviral treatment in a patient with hepatitis B virus-related decompensated cirrhosis[J].West Indian Medical Journal,2015,64(2):165-166.
[3] 李广明,刘丽娜.健脾利湿汤辅助治疗肝硬化腹水25例临床观察[J].甘肃中医药大学学报,2017,34(3):49-51.
[4] 康海燕,赵子龙,张志,等.拉米夫定联合阿德福韦酯治疗老年乙型肝炎肝硬化疗效观察[J].现代中西医结合杂志,2016,25(15):1653-1655.
[5] 胡建红.中西医联合治疗失代偿期乙型肝炎肝硬化患者的疗效研究[J].中国中西医结合消化杂志,2016,34(1):36-40.
[6] 中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[C]//第一次全国中西医结合传染病学术会议论文汇编.深圳:中国中西医结合学会传染病专业委员会,2006:62-68.
[7] 鲍旭丽,渠亚超,闾军.慢性乙型肝炎抗病毒及免疫调节治疗研究进展[J].中国中西医结合消化杂志,2016,24(6):484-487.
[8] 黎桂玉,李树民,陈永欣,等.强肝胶囊对慢性肝炎血清肝纤维化指标作用的Meta分析[J].辽宁中医杂志,2016,59(5):900-904.
[9] 梁浩卫,赵文霞.消胀利水方贴敷治疗肝硬化腹水临床疗效观察[J].中西医结合肝病杂志,2016,26(6):367-368.

备注/Memo

备注/Memo:
收稿日期:2017-11-15。
基金项目:国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教发[2014]20号)。
作者简介:徐彤(1988-),女,住院医师,医学学士,主要从事心脑血管、消化系统等疾病的临床治疗。
通信作者:袁今奇(1942-),男,主任医师,教授,医学博士,主要从事冠心病、慢性肝病及各种疑难病症的中医诊治。E-mail:yjq342@163.com
更新日期/Last Update: 1900-01-01